NCT07019766 National Longitudinal Cohort of Hematological Diseases-Large Granular Lymphocytic Leukemia
| NCT ID | NCT07019766 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China |
| Condition | T-LGL Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 9,999 participants |
| Start Date | 2000-01-01 |
| Primary Completion | 2070-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9,999 participants in total. It began in 2000-01-01 with a primary completion date of 2070-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The objectives of this study are to investigate the incidence and risk factors of large granular lymphocytic leukemia (LGLL) and to analyze the treatment effectiveness, patient prognosis, and healthcare costs in China. 1. Analyze the demographic and clinical characteristics of patients with LGLL, including sex, age, disease severity, and other relevant factors. 2. Examine disease features of LGLL patients, such as biochemical and hematological indicators, LGL counts, clonality, bone marrow pathology, and cytogenetics 3. Assess treatment patterns and real-world effectiveness in LGLL patients. 4. Evaluate clinical outcomes, including hematologic response, relapse, and mortality 5. Investigate long-term prognosis, including post-discontinuation outcomes and health-related quality of life.
Eligibility Criteria
Inclusion Criteria: * Subjects diagnosed with LGLL. * Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2000. Exclusion Criteria: * Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities). * Subject with alcohol or drug dependence that may reduce their compliance with the study. * Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07019766 clinical trial?
This trial is open to participants of all sexes, studying T-LGL Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07019766 currently recruiting?
Yes, NCT07019766 is actively recruiting participants. Contact the research team at zhanglele@ihcams.ac.cn for enrollment information.
Where is the NCT07019766 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT07019766 clinical trial?
NCT07019766 is sponsored by Institute of Hematology & Blood Diseases Hospital, China. The trial plans to enroll 9,999 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.